What the FDA labels say about taking them together
Mitoxantrone and ocrelizumab
Ocrelizumab's FDA label of May 14, 2026 names mitoxantrone in its drug interactions section; the mitoxantrone label PlainMeds reads does not name ocrelizumab.
Check it at the source: the mitoxantrone FDA label on DailyMed (effective April 24, 2025, Meitheal Pharmaceuticals Inc.); the ocrelizumab FDA label on DailyMed (effective May 14, 2026, Genentech, Inc.).
What does the mitoxantrone label say about ocrelizumab?
Mitoxantrone's label (effective April 24, 2025) does not name ocrelizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (mitoXANTRONE), Meitheal Pharmaceuticals Inc., effective April 24, 2025 (SPL set 1634528a-30c5-4309-acc8-4c0293ae14ae), via openFDA; the full label on DailyMed
What does the ocrelizumab label say about mitoxantrone?
Ocrelizumab label, drug interactionsWhen switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ].
Source: FDA drug label (OCREVUS), Genentech, Inc., effective May 14, 2026 (SPL set 9da42362-3bb5-4b83-b4bb-b59fd4e55f0d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Mitoxantrone | Ocrelizumab | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once